Answers are grounded in this paper and cite their sources.
78-year-old man with metastatic platinum refractory small cell carcinoma of the prostate who was treated with pembrolizumab with good partial response. This case supports that checkpoint inhibitors could be of a benefit for such rare cancers and more investigation is warranted.
No takes yet. Share an insight, caveat, or question.
Salhab et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: